VTN and Alzheimer disease: Multiple lines of evidence support a role for the complement system in the pathogenesis of AD [20], [21] and recent proteomic studies have implicated complement proteins in the CSF, including C3a both as biomarkers of established AD [22] as well as predictors of conversion to AD in MCI subjects [23].